All In Biotech

Drug Trial Radar · NCT06708260

A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DME

A Phase 2, Multicenter, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Two Doses of ENN0403 in Subjects With Diabetic Macular Edema (DME)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Dec 12, 2024

Primary completion

Aug 12, 2026

Study completion Aug 20, 2026

Sponsor

Lead sponsor
EnnovaBioIndustry
Sponsor type
Industry
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, parallel study to evaluate the efficacy and safety of two doses of ENN0403 in subjects with diabetic macular edema (DME). Approximately 60 subjects will be randomized to receive ENN0403 capsule orally once a day at the low dose or high dose with a 1:1 ratio. The study period consisted of up to 2 weeks of screening, 12 weeks of treatment and 2 weeks of follow-up, and the entire trial period was up to 16 weeks.

Conditions

  • Diabetic Macular Edema (DME)

Interventions

  • ENN0403, low doseDrug

    ENN0403 capsules will be orally administered once a day for 12 weeks.

  • ENN0403, high doseDrug

    ENN0403 capsules will be orally administered once a day for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Central Retinal Thickness (CRT) at week 12Time frame: week 12

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Shijiazhuang People's Hospital

    Shijiazhuang, Hebei, China

  • Hebei Eye Hospital

    Xingtai, Hebei, China

  • Zhengzhou Second Hospital

    Zhengzhou, Henan, China

  • Affiliated Hospital of Shandong Second Medical University

    Weifang, Shandong, China

  • Shanghai Eye Disease Prevention and Treatment Center

    Shanghai, Shanghai Municipality, China

  • Shanxi Eye Hospital

    Taiyuan, Shanxi, China

  • Xian No.1 Hospital

    Xi’an, Shanxi, China

  • Hospital of Chengdu University of TCM

    Chengdu, Sichuan, China

  • Tianjin Medical University Eye Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.